[1]CurrentPatentAssignee:PFIZERINC-WO2005/13986,2005,A1Locationinpatent:Page/Pagecolumn32
[1]JournalofMedicinalChemistry,2007,vol.50,p.2647-2654
[1]Patent:US2007/142414,2007,A1.Locationinpatent:Page/Pagecolumn19
Title: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Journal: Journal of medicinal chemistry 20101028
Title: Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
Journal: Journal of medicinal chemistry 20100923
Title: First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Journal: Journal of medicinal chemistry 20090122
Title: A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Journal: Nature chemical biology 20080601
Title: Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
Journal: Journal of medicinal chemistry 20080214
Title: Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Journal: Journal of medicinal chemistry 20070531
Title: Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300.
Title: Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196-204.
Title: Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.
Title: Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.
